The MEDIOLA trial showed high objective response rates with durvalumab (anti–PD-L1 antibody) and olaparib in patients with germline BRCA-mutated (gBRCAm), platinum-sensitive recurrent ovarian cancer and benefit of durvalumab-olaparib-bevacizumab triple therapy in patients with non–gBRCAm platinum-sensitive recurrent ovarian cancer.51 The gene discussed is CD274; the disease is ovarian cancer.